Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Leiper, Keith; Martin, Kate; Ellis, Anthony; Subramanian, Sreedhar; Watson, Alastair; Christmas, Stephen E.; Howarth, Deborah; Campbell, Fiona; Rhodes, Jonathan M.

doi:10.1136/gut.2010.225482

Cited by 125 publications

(73 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, RTX was not associated with worsening of UC in a double-blinded randomized controlled trial consisting of 24 patients with moderately active UC 10 .…”

Section: To the Editormentioning

confidence: 99%

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis

2016

View full text Add to dashboard Cite

“…Conversely, RTX was not associated with worsening of UC in a double-blinded randomized controlled trial consisting of 24 patients with moderately active UC 10 .…”

Section: To the Editormentioning

confidence: 99%

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis

2016

View full text Add to dashboard Cite

“…Due to its theoretical effects on B cells; it was also tested in steroid resistant UC patients. The rate of induction of remission was similar in the rituximab compared to placebo [74]. However; rituximab was observed to exacerbate the symptoms of UC in one case [75] and de novo UC developed in some patients treated with rituximab due to other conditions like nephrotic syndrome [76]; follicular lymphoma [77] and Grave's disease [78].…”

Section: Modifying T Cell Functionsmentioning

confidence: 83%

Novel Drug Therapies for the Treatment of Crohn's Disease

Miheller¹

2015

J Gastrointest Dig Syst

View full text Add to dashboard Cite

show abstract

“…Rituximab may be an alternative to immunosuppressive therapies for difficult-to-treat nephrotic syndrome as it is known to assist tapering steroids [15,16]. It may also play a role in IBD control [17].…”

Section: Discussionmentioning

confidence: 99%

Nephrotic Syndrome after Infliximab Treatment in a Patient with Ulcerative Colitis

Dumitrescu

Dahan

Corcos

et al. 2015

JGLD

View full text Add to dashboard Cite

Tumor necrosis factor (TNF)-targeted therapies are increasingly used to treat a variety of inflammatory and autoimmune diseases. They are now used worldwide, and this class of medication has revolutionized the treatment of these diseases and the quality of life for patients but it also poses risk of developing various side effects including infections, exacerbation of some neurological manifestations, cutaneous lesions or induces antibody production. Renal complications are uncommon and poorly recognized. This report describes a probable case of infliximab-induced focal segmental glomerulosclerosis clinically presented as a severe nephrotic syndrome in a patient with ulcerative colitis.

show abstract

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Abstract: NCT00261118.

Cited by 125 publications

References 33 publications

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis

Novel Drug Therapies for the Treatment of Crohn's Disease

Nephrotic Syndrome after Infliximab Treatment in a Patient with Ulcerative Colitis

Contact Info

Product

Resources

About